Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis
Clinical and Vaccine Immunology, Volume 13, No. 2, Year 2006
Notification
URL copied to clipboard!
Description
Mycobacterium tuberculosis is estimated to infect 80 to 100 million people annually, the majority of whom do not develop clinical tuberculosis (TB) but instead maintain the infection in a latent state. These individuals generally become positive in response to a tuberculin skin test and may develop clinical TB at a later date, particularly if their immune systems are compromised. Latently infected individuals are interesting for two reasons. First, they are an important reservoir of M. tuberculosis, which needs to be considered for TB control. Second, if detected prior to recrudescence of the disease, they represent a human population that is making a protective immune response to M. tuberculosis, which is very important for defining correlates of protective immunity. In this study, we show that while responsiveness to early secretory antigenic target 6 is a good marker for M. tuberculosis infection, a strong response to the 16-kDa Rv2031c antigen (HspX or α-crystallin) is largely restricted to latently infected individuals, offering the possibility of differential immunodiagnosis of, or therapeutic vaccination against, TB. Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Authors & Co-Authors
Demissie, Abebech
Ethiopia, Addis Ababa
Armauer Hansen Research Institute
Leyten, Eliane Madeleine Sophie
Netherlands, Leiden
Leids Universitair Medisch Centrum
Abebe, Markos
Ethiopia, Addis Ababa
Armauer Hansen Research Institute
Wassie, Liya
Ethiopia, Addis Ababa
Armauer Hansen Research Institute
Aseffa, Abraham
Ethiopia, Addis Ababa
Armauer Hansen Research Institute
Abate, Getahun
Ethiopia, Addis Ababa
Armauer Hansen Research Institute
United States, St. Louis
St. Louis University School of Medicine
Fletcher, Helen A.
United Kingdom, London
Ucl Medical School
United Kingdom, Oxford
Nuffield Department of Medicine
Owiafe, Patrick K.
Gambia, Banjul
Medical Research Council Laboratories Gambia
Hill, Philip C.
Gambia, Banjul
Medical Research Council Laboratories Gambia
Brookes, Roger H.
Gambia, Banjul
Medical Research Council Laboratories Gambia
Rook, Graham A.W.
United Kingdom, London
Ucl Medical School
Zumla, A. I.
United Kingdom, London
Ucl Medical School
Arend, Sandra M.
Netherlands, Leiden
Leids Universitair Medisch Centrum
Klein, Michél R.
Netherlands, Leiden
Leids Universitair Medisch Centrum
Ottenhoff, Tom H.M.
Netherlands, Leiden
Leids Universitair Medisch Centrum
Andersen, Peter Lawætz
Denmark, Copenhagen
Statens Serum Institut
Doherty, Timothy Mark
Denmark, Copenhagen
Statens Serum Institut
Statistics
Citations: 214
Authors: 17
Affiliations: 7
Identifiers
Doi:
10.1128/CVI.13.2.179-186.2006
ISSN:
15566811
Research Areas
Infectious Diseases
Study Design
Cross Sectional Study